Advancing Autologous iPSC-Derived Dopaminergic Neurons Clinical Development

• Presenting safety and engraftment data from an iPSC-derived neuronal therapy in Parkinson’s disease
• Evaluating early clinical signals and defining meaningful endpoints for regenerative neurology
• Demonstrating manufacturing comparability and critical quality attribute control while scaling toward pivotal development
• Aligning CMC and regulatory strategy to support durability claims and patient follow-up

Speakers:

Ron Cohen

Chief Executive Officer

Oryon Cell Therapies